2016 American Transplant Congress
A Comprehensive Biomarker Study to Compare Tacrolimus and Mycophenolic Acid versus Half-Dose Tacrolimus and Everolimus in De Novo Kidney Transplant Patients in the Novartis US92 Study.
In this exploratory biomarker sub-study, a comprehensive combined targeted/ non-targeted metabolomics and targeted proteomics approach was used to assess potential differences between the everolimus+ low-dose…2016 American Transplant Congress
Impact of Early Calcineurin Inhibitor Withdrawal on Renal Function and Urinary Protein Excretion: 24 Month Analyses of the ELEVATE Study.
Background: Proteinuria is a biomarker which helps in predicting graft outcomes in kidney transplant recipients (KTxRs). The ELEVATE study was designed to determine whether an…2016 American Transplant Congress
Rapid Discontinuation of Prednisone (RDP) in Kidney Transplant (KTx) Recipients: 15-Year Outcomes.
PURPOSE: RDP after KTx is associated with increased early rejection; no decrease in medium‐term patient (PS) or graft survival (GS); and significantly decreased prednisone‐related side…2016 American Transplant Congress
Better Long-Term Renal Function with Lower Incidence of Acute Rejection and Lower CMV Infection in Renal Transplant Patients Treated with a Combination of Tacrolimus and Everolimus.
Surgery - Renal Transplant Unit, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction. Recent clinical trials have shown that the combination of CNIs with Everolimus (EVE) allows CNIs minimization, which may positively impact on chronic nephrotoxicity. Aim…2016 American Transplant Congress
Evaluation According to Donor Source: 24-Month Results from Post-Hoc Analysis of the ELEVATE Study in Kidney Transplant Recipients.
ELEVATE study group, Leiden, Netherlands.
Background: Several studies reported that recipients receiving renal allograft from living donors have better efficacy outcomes than the deceased donor counterparts. This post-hoc analysis of…2016 American Transplant Congress
Efficacy and Renal Function in Kidney Transplant Recipients Receiving Tacrolimus (TAC)-Based Immunosuppressive Regimens in Combination with Everolimus (EVR) versus Mycophenolate (MPA).
Nephrology Division, Hospital do Rim - UNIFESP, Sao Paulo, Brazil.
Acute rejection and renal function are associated with long-term renal allograft survival. We evaluated these outcomes in patients receiving reduced TAC exposure combined with EVR…2015 American Transplant Congress
Renal Allografts Demonstrate Improved Pathology After Belatacept Therapy
1University of Maryland School of Medicine, Baltimore; 2Johns Hopkins University, Baltimore.
Belatacept provides immunosuppression via costimulation blockade and has been associated with improved renal function compared to calcineurin inhibitor based therapies. We developed the Maryland Aggregate…2015 American Transplant Congress
A Prospective Study of Renal Function and Histological Changes in Renal Transplant Recipients With Acute Clinical and Subclinical Rejection
Background: To study the impact on renal function and histological changes in patients(pts) with acute clinical rejection(ACR) and subclinical rejection(SCR) from 3 to 12 month(m)…2015 American Transplant Congress
Utilization of Kidneys from Deceased Donors With Acute Kidney Injury
Division of Transplant Surgery, NewYork-Presbyterian/Weill Cornell Medical College, New York.
Due to the shortage of kidneys available for transplantation and the morbidity and mortality that occurs while patients wait for a transplant, utilization of organs…2015 American Transplant Congress
African American Race Is an Independent Risk Factor for Cytomegalovirus Infection in Renal Transplant Recipients on Low-Dose Valganciclovir Prophylaxis
Houston Methodist Hospital, Houston, TX.
Safe and effective use of low-dose (450 mg/day) valganciclovir (VGC) for cytomegalovirus (CMV) prophylaxis in renal transplant recipients (RTRs) has been reported. However, it is…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- 27
- Next Page »